Evidence
Original publication
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. Five pretreatment factors (age > 60, raised LDH, ECOG ≥ 2, Ann Arbor III–IV, > 1 extranodal site) defined four risk groups with 5-year overall survival of 73%, 51%, 43% and 26%.
New England Journal of Medicine, 1993
Validation
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Regroups the score into very good (0), good (1–2) and poor (3–5), with 4-year progression-free survival of 94%, 80% and 53%.
Blood, 2007
Guideline
The IPI (and disease-specific variants: R-IPI, NCCN-IPI, and for follicular lymphoma the FLIPI) is a prognostic tool used for counselling and trial stratification, not a treatment selector. Age-adjusted IPI (stage, LDH, performance status) is used for patients ≤ 60 years.
Last reviewed: 2026-09
Report an error in this calculator
MedScore is an educational and clinical decision-support tool. It does not provide a diagnosis, a treatment, or a drug-dosing recommendation, and it does not replace clinical judgement or local guidelines. Confirm every result against the original source before acting on it. The treating clinician remains responsible for all decisions.